Substitution infusion fluid and citrate anticoagulation
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61M-001/34
A61K-033/00
A01N-001/02
출원번호
US-0959543
(2001-10-23)
우선권정보
EP-0201302 (1999-04-26)
국제출원번호
PCT/EP00/03583
(2000-04-20)
국제공개번호
WO00/64456
(2000-11-02)
발명자
/ 주소
Chang, Pe Chou
출원인 / 주소
Edwards Lifesciences AG
대리인 / 주소
Vinitskaya, Lena I.
인용정보
피인용 횟수 :
19인용 특허 :
44
초록▼
The invention relates to a substitution infusion fluid for hemofiltration of a specific composition. The use of said substitution infusion fluid significantly reduces the risk of the occurrence of abnormalities in a patient undergoing pure hemofiltration. The invention also relates to process for pu
The invention relates to a substitution infusion fluid for hemofiltration of a specific composition. The use of said substitution infusion fluid significantly reduces the risk of the occurrence of abnormalities in a patient undergoing pure hemofiltration. The invention also relates to process for pure hemofiltration of blood wherein said substitution infusion fluid is used. The invention also relates to a matching citrate anticoagulation fluid of a specific composition. The invention also relates to a process for pure hemofiltration of blood wherein said substitution infusion fluid is used in combination with said citrate anticoagulation fluid. The use of said substitution infusion fluid in combination with said citrate anticoagulation fluid significantly further reduces the risk of the occurrence of abnormalities in a patient undergoing pure hemofiltration.
대표청구항▼
1. An a queous substitution infusion fluid for pure hemofiltration of blood using citrate as anticoagulant comprising: between 0.2 and 1 mmol/L of dihydrogen phosphate ions; between 70 and 130 mmol/L of sodium ions; between 1.6 and 2.6 mmol/L of calcium ions; between 0.25 and 1.25 mmol/L
1. An a queous substitution infusion fluid for pure hemofiltration of blood using citrate as anticoagulant comprising: between 0.2 and 1 mmol/L of dihydrogen phosphate ions; between 70 and 130 mmol/L of sodium ions; between 1.6 and 2.6 mmol/L of calcium ions; between 0.25 and 1.25 mmol/L of magnesium ions; between 1 and 4 mmol/L of potassium ions; between 3 and 11.5 mmol/L of glucose; below 5.5 mmol/L of acetate ions; and chloride ions to keep electrochemical balance. 2. The substitution infusion fluid according to claim 1, comprising between 0.4 and 0.8 mmol/L of dihydrogen phosphate ions.3. The substitution infusion fluid according to claim 1 comprising between 90 and 110 mmol/L of sodium ions.4. The substitution infusion fluid according to claim 1 comprising between 1.9 and 2.3 mmol/L of calcium ions.5. The substitution infusion fluid according to claim 1 comprising between 0.5 and 1 mmol/L of magnesium ions.6. The substitution infusion fluid according to claim 1 comprising between 1.8 and 3.5 mmol/L of potassium ions.7. The substitution infusion fluid according to claim 1 comprising between 5.5 and 7.5 mmol/L of glucose.8. The substitution infusion fluid according to claim 1 comprising between 0 and 3.1 mmol/L of acetate ions.9. The substitution infusion fluid according to claim 1 comprising between 0 and 3.1 mmol/L of bicarbonate ions.10. The substitution infusion fluid according to claim 1 comprising amino acids and/or trace elements.11. An aqueous substitution infusion fluid for pure hemofiltration of blood using citrate as anticoagulant comprising about 100 mmol/L of sodium ions, about 2.1 mmol/L of calcium ions, about 2.2 mmol/L of potassium ions, about 0.6 mmol/L of phosphate ions, about 0.8 mmol/L of magnesium ions, about 7.0 mmol/L of glucose, less than 3.1 mmol/L of acetate ions, and chloride ions to keep electrochemical balance. 12. An aqueous substitution infusion fluid for pure hemofiltration of blood using citrate as anticoagulant comprising about 107 mmol/L of sodium ions, about 2.3 mmol/L of calcium ions, about 2.5 mol/L of potassium ions, about 0.8 mmol/L of phosphate ions, about 0.9 mmol/L of magnesium ions, about 6.4 mmol/L of glucose, less than 5.5 mmol/L of acetic acid, and chloride ions to keep electrochemical balance. 13. An aqueous substitution infusion fluid for pure hemofiltration of blood using citrate as anticoagulant comprising about 118 mmol/L of sodium ions, about 2.3 mmol/L of calcium ions, about 2.6 mmol/L of potassium ions, about 0.8 mmol/L of phosphate ions, about 0.9 mmol/L of magnesium ions, about 6.5 mmol/L of glucose, less than 5.5 mmol/L of acetic acid, and chloride ions to keep electrochemical balance. 14. The substitution infusion fluid for pure hemofiltration according to claim 1 further comprising iron ions, and/or zinc ions, and/or copper ions, and/or manganese ions, and/or water-soluble vitamins.15. The substitution infusion fluid for pure hemofiltration according to claim 1 further comprising between 0.5 and 5.5 mmol/L of acetic acid.16. The substitution infusion fluid for pure hemofiltration according to claim 1 further comprising a matching citrate anticoagulation solution comprising between 19 and 135 mmol/L of citric acid and between 106 and 290 mmol/L of trisodium citrate.17. A citrate anticoagulation solution for anticoagulation of circulating blood during pure hemofiltration, comprising between 19 and 135 mmol/L of citric acid and between 106 and 290 mmol/L of trisodium citrate. 18. A citrate anticoagulation solution for anticoagulation during pure hemofiltration of blood being an aqueous solution comprising about 38 mmol/L of citric acid and about 212 mmol/L of trisodium citrate. 19. A pure hemofiltration process for blood comprising: a) providing blood to an artificial kidney via an extracorpeal circuit; b) adding a citrate/citric acid anticoagulant to the blood prior to entering the artificial kidney; c) filtering the blood using a semi -permeable membrane; d) adding a hemofiltration substitution fluid according to claim 1 back to the filtered blood; e) returning the filtered blood containing the substitution fluid back to the patient; and wherein said anticoagulant and said substitution fluid are matched to provide for consistent concentrations of systemic electrolytes in a patient undergoing hemofiltration.20. The pure hemofiltration process according to claim 19 wherein said systemic electrolytes comprise the group consisting of chloride, sodium, potassium, phosphate, calcium, magnesium, bicarbonate and combinations thereof.21. A kit for performing hemofiltration comprising: a citrate/citric acid anticoagulant composition and a matched substitution fluid according to claim 1 that provide for consistent concentrations of systemic electrolytes in a patient undergoing hemofiltration.22. The kit according to claim 21 wherein said citrate/citric acid composition is provided in a substantially liquid form.23. The kit according to claim 21 wherein said citrate/citric acid composition is provided in a substantially solid form.24. The kit according to claim 21 wherein said substitution fluid is provided in a substantially liquid form.25. The kit according to claim 21 wherein said substitution fluid is provided in a substantially solid form.26. The according to claims 21 or24 wherein said substitution fluid is hypotonic.27. The according to claim 21 wherein said citric acid composition and21 wherein said substitution fluid are sterile.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (44)
Kartinos Nicholas J. (5651 E. Rocky Mountain Ave. Park Ridge IL) McGary Terry J. (5651 E. Rocky Mountain Ave. Columbia MO 65201) Nolph Karl D. (801 Westport Columbia MO 65201), Additives for peritoneal dialysis solutions.
Duponchelle Annick,BEX ; Faict Dirk,BEX ; Balteau Patrick,BEX ; Hartman Jean-Pierre,BEX ; Martis Leo ; Peluso Francesco,BEX, Bicarbonate-based solution in two parts for peritoneal dialysis or substitution in continuous renal replacement therapy.
Shockley Ty R. (Highland Park IL) Martis Leo (Long Grove IL) Henderson Lee W. (Lake Forest IL) Moran John (Evanston IL) Nakayama Masaaki (Tokyo JPX), Low sodium peritoneal dialysis solution.
Shockley Ty R. (Highland Park IL) Martis Leo (Long Grove IL) Henderson Lee W. (Lake Forest IL) Moran John (Evanston IL) Nakayama Masaaki (Tokyo JPX), Low sodium peritoneal dialysis solution.
Shockley Ty R. (Highland Park IL) Martis Leo (Long Grove IL) Henderson Lee W. (Lake Forest IL) Moran John (Evanston IL) Nakayama Masaaki (Tokyo JPX), Low sodium peritoneal dialysis solution.
Breborowicz Andrzej,PLX ; Oreopoulos Dimitrios G.,CAX, Peritoneal dialysis solutions and methods usable to minimize the injury and adverse physiological effects caused by peri.
Martis Leo ; Burke Ron ; Shockley Ty ; Henderson Lee W. ; Faller Bernadette,FRX, Peritoneal dialysis solutions containing maltodextrins and amino acids.
Frster Harald (Frankfurt am Main DEX) Asskali Fatima (Frankfurt am Main DEX) Nitsch Ernst (Linz ATX), Pharmaceutical composition for peritoneal dialysis.
Fressinet, Jean Louis; Zaccarelli, Massimo; Artioli, Gianluca; Letteri, Jeffrey J., Device for calculating blood flow in an extracorporeal blood circuit, and an apparatus for treatment of blood using the device.
Ernebrant, Malin; Bertinsson, Gert-Inge; Linden, Torbjörn; Olsson, Lars-Fride; Sandström, Theodor; Svensson, Therese; Wieslander, Anders, Medical solution, a method for producing said medical solution and use thereof.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.